Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19

This dataset comprises single-cell RNA-Seq data of nasopharyngeal samples of 32 COVID-19
patients and 16 healthy controls, for a total of 48 samples. 25 COVID-19 patients and 10 controls were diagnosed with hypertension and treated with either ACE inhibitors (ACEi) or angiotensin receptor blockers(ARB) (SARS-CoV-2-positive: 10 ACEi and 15 ARB; SARS-CoV-2-negative: 6 ACEi and 4 ARB).
An
in-depth description is presented in the manuscript "Delayed viral clearance and exacerbated airway hyperinflammation in hypertensive COVID-19 patients"
(https://www.medrxiv.org/content/10.1101/2020.09.22.20199471v1).

本数据集包含32例新型冠状病毒肺炎（COVID-19）患者与16名健康对照者的鼻咽样本单细胞RNA测序（single-cell RNA-Seq）数据，总计48份样本。其中25例COVID-19患者与10名健康对照者被确诊为高血压，并接受了血管紧张素转换酶抑制剂（ACE inhibitors, ACEi）或血管紧张素Ⅱ受体拮抗剂（angiotensin receptor blockers, ARB）治疗；具体分组为：严重急性呼吸综合征冠状病毒2型（SARS-CoV-2，即新冠病毒）检测阳性者中，10例使用ACEi、15例使用ARB；SARS-CoV-2检测阴性者中，6例使用ACEi、4例使用ARB。本数据集的详细描述刊载于题为《高血压合并新型冠状病毒肺炎患者的病毒清除延迟与气道高炎症加剧》的手稿（https://www.medrxiv.org/content/10.1101/2020.09.22.20199471v1）